Plecanatide and linaclotide are the two FDA-approved peptide drugs in the guanylate cyclase-C (GC-C) agonist class, both used for chronic constipation and irritable bowel syndrome with constipation (IBS-C). Because they share a drug class and a similar mechanism, they're often compared directly. Here's how they actually differ.
Shared Mechanism, Different Templates
Both drugs activate GC-C receptors on the lining of the small intestine, triggering fluid secretion into the gut that softens stool and increases bowel movement frequency. Where they differ is which natural peptide each one was modeled on. Linaclotide (Linzess) is structurally based on guanylin and the heat-stable enterotoxin produced by certain E. coli strains (which also activates GC-C receptors), while plecanatide (Trulance) is structurally based on uroguanylin, a related but distinct natural peptide hormone. Both are minimally absorbed into the bloodstream, so their effects are intended to stay largely local to the gut.
Approved Uses
Linaclotide was approved first, receiving FDA clearance in 2012 for both chronic idiopathic constipation and IBS-C, and later gained a pediatric indication for functional constipation in children ages 6 and up. Plecanatide followed in 2017 for chronic idiopathic constipation, with an IBS-C indication added in 2018; it is not approved for use in children. Both are taken as once-daily oral tablets, though linaclotide is typically taken on an empty stomach while plecanatide can be taken with or without food.
Trial Results
Across their respective Phase 3 programs, both drugs showed statistically significant improvements over placebo on their respective trial endpoints — measures combining bowel movement frequency with reductions in abdominal pain. In plecanatide's IBS-C trials, "Overall Responder" rates were 21.5% (3 mg) and 24.0% (6 mg) versus 14.2% on placebo. The two drugs have not been tested against each other directly in a head-to-head trial, so any comparison of their relative effectiveness relies on separate placebo-controlled trials with different designs, populations, and time periods — a real limitation for anyone trying to judge which drug "works better."
Side Effects
Diarrhea is the most common side effect for both drugs and the leading reason patients discontinue either one. Reported diarrhea rates vary somewhat by trial and dose, and because the two drugs haven't been studied head-to-head, it isn't possible to say with confidence that one causes meaningfully less diarrhea than the other based on cross-trial comparisons alone. Both drugs carry an FDA boxed warning against use in children younger than 6, reflecting a juvenile-animal finding of severe, sometimes fatal dehydration at that age; linaclotide's additional approval for constipation in children 6 and older came with specific pediatric trial data supporting that older age range, which plecanatide does not have.
What Isn't Settled
Without a direct comparative trial, questions like which drug produces faster relief, which has a more favorable long-term side-effect profile, and which is more effective at a population level remain genuinely open. Insurance formulary status, cost, and an individual's prior response to one drug or the other often end up mattering more in practice than any small differences suggested by separate trials.
The Bottom Line
Plecanatide and linaclotide are close cousins rather than meaningfully different options: same receptor target, similar mechanism, overlapping approved uses, and a shared most-common side effect. The practical choice between them is usually driven by a patient's age, prior treatment history, and a physician's clinical judgment rather than by a clear efficacy edge, since no trial has directly tested one against the other.